Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial - Test2 - elhamkhani - TriplyDB

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

http://www.wikidata.org/entity/Q28253329

about

Prognostic biomarkers in acute coronary syndrome Targeting interleukin-1 in heart disease State of the Art: Newer biomarkers in heart failure Emerging risk biomarkers in cardiovascular diseases and disorders Novel biomarkers for cardiovascular risk prediction.Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes?Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome Associations of Circulating Growth Differentiation Factor-15 and ST2 Concentrations With Subclinical Vascular Brain Injury and Incident Stroke Storage Time and Urine Biomarker Levels in the ASSESS-AKI Study Prognostic Value of Soluble ST2 During Hospitalization for ST-Segment Elevation Myocardial Infarction.Multimarker Risk Stratification in Patients With Acute Myocardial Infarction Comparison Between Soluble ST2 and High-Sensitivity Troponin I in Predicting Short-Term Mortality for Patients Presenting to the Emergency Department With Chest Pain.Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events.The Presage(®) ST2 Assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2.ST2 as a cardiovascular risk biomarker: from the bench to the bedside.The use of biomarkers in the patient with heart failure.A novel cardiac bio-marker: ST2: a review.Risk assessment of post-infarction heart failure. Systematic review on the role of emerging biomarkers.Using ST2 in cardiovascular patients: a review.Natural history and therapy of AL cardiac amyloidosis.Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.Improved early risk stratification of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention using a combination of serum soluble ST2 and NT-proBNP.Candidate biomarkers in heart failure with reduced and preserved ejection fraction.Clinical relevance of sST2 in cardiac diseases.Novel Risk Stratification Assays for Acute Coronary Syndrome.Prognostic value of plasma biomarkers in patients with acute coronary syndrome: a review of advances in the past decade.ST2 may not be a useful predictor for incident cardiovascular events, heart failure and mortality.Prognostic Biomarkers in Acute Coronary Syndromes: Risk Stratification Beyond Cardiac Troponins.Temporal changes of soluble ST2 after cardiovascular interventions.Increased Plasma Concentrations of Soluble ST2 Independently Predict Mortality but not Cardiovascular Events in Stable Coronary Heart Disease Patients: 13-Year Follow-up of the KAROLA Study.Galectin-3, a marker of cardiac remodeling, is inversely related to serum levels of marine omega-3 fatty acids. A cross-sectional study.Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicity-2.Compelling Benefit of Soluble Suppression of Tumorigenicity-2 in Post-Myocardial Infarction Estimation of Risk: The Time Is Right for Its Routine Use in the Clinic.Prognostic Value of Soluble ST2 After Myocardial Infarction: A Community Perspective.Multibiomarker analysis in patients with acute myocardial infarction.Soluble ST2 in end-stage heart failure, before and after support with a left ventricular assist device.Long-term systolic function in children and young adults after hematopoietic stem cell transplant.The injured heart: early cardiac effects of hematopoietic stem cell transplantation in children and young adults.Prognostic Utility of Soluble Suppression of Tumorigenicity 2 level as a Predictor of Clinical Outcomes in Incident Hemodialysis Patients.

P2860

Q26738521-2D313115-5EEF-4745-ADC0-C16775F9DA0E Q27009347-05ECB89E-C942-47FA-BFEB-EF0B0D92BF9D Q27027899-5CC7FD86-3559-4EA8-AF51-5CCA591BB328 Q28081614-EFF4052B-2CF9-4369-B675-AF5A0FDC706C Q33615459-CC5187D1-8879-408C-9B88-3D8F2D35BB85 Q34462325-4FD978C7-4D08-4C3C-9C08-7F8BD395C97D Q35153947-F5DE4653-67C6-4755-A052-20EA56C69252 Q35998337-E61F61B1-FB4F-4273-9A34-46BEDC3CEE3E Q36176098-2BCCF59D-E71F-4657-B18B-96A1A2684035 Q36864318-D9D2700C-2D97-41E1-BAC1-B73E465D22BB Q36956650-3578A068-9C5D-4DDE-84D6-B69E83A03C7D Q37547780-F27AAB1D-F586-4AD5-B7C5-608ACF8D80C6 Q38008700-50B6EF8C-C3EB-4EED-BF45-8158AD96167C Q38068933-CD818BEC-D145-40A8-95BE-EA7F7C111567 Q38096251-08B07717-EF36-4709-86CF-3A32DE38B9BE Q38104269-725D005F-798D-45DE-89D1-98544285201D Q38171069-192E7712-8F0E-4388-862C-ACF3B380F0D6 Q38177341-4BD70978-AE4B-49A6-8C2E-41E7A09DF7EA Q38258665-CECA412E-2EB5-4955-B3E8-5CF6A6A87D93 Q38275212-10460FFE-0285-4E8E-8C6B-636999072AEB Q38370866-78E38E82-9AD6-4D24-B165-4D032049A3A6 Q38380593-E78213E4-B136-46D7-936F-0C99438A439A Q38400116-387ED9E8-0643-454F-9D2C-9CE9C44A2DE6 Q38572500-3E06F048-5347-4DC1-BCC5-AD519B50B6FD Q38626970-54BBB086-53B2-4890-9E28-F382BE1B4051 Q38666324-52FD7E21-DDFA-4185-8D07-6018D3342018 Q38810989-C12FFFFA-2E2C-49D8-8000-6A8CFE7C4AA4 Q39150426-BCB05C85-8903-4D17-9BE5-6655FE537C35 Q39185614-9C8D50B6-AA26-4E00-B5A6-98A70EFBA44D Q39507885-B22A746A-1D2E-4C3C-A008-D039A935F208 Q40297133-61C5A737-64EA-4A1C-9FD8-53B5AC38D8CD Q41716070-BDC105C9-1370-48CD-9134-6125E5B6C300 Q47138839-27F46C86-B816-4F87-B3B0-972BC619CD45 Q47144393-82D0AB5E-8207-4E75-874D-34933D770B11 Q47815486-08437EC9-678E-4858-BB8A-2179C0F84992 Q48165741-C8C47AE3-E4AA-49B0-81C9-E37E0F0F6143 Q48258807-2C06368E-19CA-4FB7-8278-64835B066E93 Q50527749-0E96FBF6-C561-4A47-9008-54DB846F1CAC Q52777491-7D1276D4-CA5B-461F-80CB-1BF78F8BE1E6 Q55344680-DDD017DF-1250-47FD-8EF8-E049BD8E31B0

P2860

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

http://www.wikidata.org/entity/Q28253329

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

@ast

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

@en

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

@nl

type

label

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

@ast

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

@en

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

@nl

prefLabel

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

@ast

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

@en

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

@nl

P1433

Q28253329-BD9C94A7-3886-443F-B2FC-073310ED201E

P1476

Q28253329-28205393-5FD5-445F-85D2-C8294EFA9C1B

P2093

Q28253329-1F3A0FB7-ED05-4992-9EF5-7E4665ED8B70

Q28253329-2B3A09BA-E923-4E2C-9C65-5818A3B20E30

Q28253329-2B70C184-1996-4335-8074-D25048DDDEED

Q28253329-6E8AAC77-9F9D-47DB-90B1-15E79CBFF96A

Q28253329-90FC482F-1322-454E-B3A8-5C308A3052A6

Q28253329-A32BEFD1-2F51-40A8-AB13-2F6812388C9F

Q28253329-A9509977-20D8-41BC-AC01-800625EE15A7

Q28253329-E27A63CC-F809-491D-A9C4-A28AA70F0EC7

Q28253329-EB7A4F80-8BBE-44C6-8946-14042AC7AE08

P2860

Q28253329-069352C8-7FB3-4E15-B1F1-E305E76CE7AA

Q28253329-072442E4-4337-4932-8BED-7ECDF6F27482

Q28253329-1168A0DC-EFDB-4B8D-AA7A-509A02FDF3BE

Q28253329-153BE217-9477-400C-8E08-EF2D88A2D4AD

Q28253329-16E3ED11-CA20-4C88-B447-815A372F4D78

Q28253329-283EFCC7-2EB5-448C-9BA6-E4EB4D9D1198

Q28253329-383733C3-75BE-4714-96E8-941D29453610

Q28253329-4C9320DC-43AE-46F0-8137-E2BDDE3A27A4

Q28253329-51CA891D-D921-441F-80DA-906D2CFAA5E2

Q28253329-52B97A97-1766-4232-8BC4-1153F4915E6F

P304

Q28253329-560B56F9-0DB1-4381-A6C2-FFB416D46724

P31

Q28253329-0B832740-6BF0-43DB-967B-220FB8F2D19D

P3181

Q28253329-6B9766B0-5E65-4796-8C29-C33D80B098BC

P356

Q28253329-FD8890AC-B908-463E-8C4F-D4C04F2F7DDF

P407

Q28253329-8CF7471F-AE19-410B-892A-18D0170C41FB

P433

Q28253329-E65087DC-10F6-4A1B-90AA-10081355F113

P478

Q28253329-69145F0A-BD89-40BD-BCAB-9A1B6FDF8391

P50

Q28253329-2C465D81-AD7D-4E27-9E35-F2B081FB163D

P577

Q28253329-3739CF80-4100-4076-B53F-ABB5EB50D3EE

P5875

Q28253329-73D71E69-59A4-4138-8A16-5710FA882AFB

P698

Q28253329-F8833F47-A7CF-4FA1-B27C-17A4BD495403

P921

Q28253329-47D32250-810E-4EB6-947C-220A1C5D73D6

P932

Q28253329-B2C708D1-82A6-4278-906B-059B285DA8C2

P3181

P356

CLINCHEM.2011.173369

P1433

Clinical Chemistry

P1476

Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial

@en

P2093

Anastacia Y Kudinova

http://www.w3.org/2001/XMLSchema#string

Benjamin M Scirica

http://www.w3.org/2001/XMLSchema#string

David A Morrow

http://www.w3.org/2001/XMLSchema#string

Marc P Bonaca

http://www.w3.org/2001/XMLSchema#string

Marc S Sabatine

http://www.w3.org/2001/XMLSchema#string

Payal Kohli

http://www.w3.org/2001/XMLSchema#string

Rahul Kakkar

http://www.w3.org/2001/XMLSchema#string

Richard T Lee

http://www.w3.org/2001/XMLSchema#string

Sabina A Murphy

http://www.w3.org/2001/XMLSchema#string

P2860

Universal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction

IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines

T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function

Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction

Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction

ST2: a novel remodeling biomarker in acute and chronic heart failure

Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure

Secreted and membrane-bound isoforms of T1, an orphan receptor related to IL-1-binding proteins, are differently expressed in vivo

IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system

IL-33 reduces the development of atherosclerosis

P304

257-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

330408

http://www.w3.org/2001/XMLSchema#string

P356

10.1373/CLINCHEM.2011.173369

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Eugene Braunwald

P577

2012-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51811081

http://www.w3.org/2001/XMLSchema#string

P698

22096031

http://www.w3.org/2001/XMLSchema#string

P921

clinical chemistry

P932

4277435

http://www.w3.org/2001/XMLSchema#string